Overview

Targeting Anhedonia in Cocaine Use Disorder

Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine anhedonia as a potential moderator of treatment outcomes for Cocaine Use Disorder (CUD). Specifically, this study will investigate how anhedonia affects outcomes in contingency management (CM) treatment for CUD and whether anhedonia mediates the effects of adjunctive treatment with a dopaminergic (DAergic) drug, d-amphetamine, on outcomes in CM for CUD, as well as investigate the contribution of anhedonia to overall CUD severity.
Phase:
Phase 2
Details
Lead Sponsor:
The University of Texas Health Science Center, Houston
University of Illinois at Chicago
Collaborator:
The University of Texas Health Science Center, Houston
Treatments:
Amphetamine
Cocaine
Dextroamphetamine